OpenNeedle Ask your own

Question explored with the scientific record

Is there a marker for genetic high cholesterol

Sep 18, 2026 · 6 sources used · OpenNeedle synthesis
Yes, there are well-established genetic markers for inherited high cholesterol, primarily in three genes.

The strongest marker is a mutation in the LDLR gene, which encodes the LDL receptor. This is the most common cause of familial hypercholesterolemia (FH), accounting for 52-76% of cases globally [3]. Over 60 different LDLR mutations have been cataloged in some populations [4]. A second marker is a mutation in the APOB gene, which affects how LDL particles bind to the receptor, found in 2-10% of cases [3]. A third, less common marker is a mutation in the PCSK9 gene, which increases the destruction of LDL receptors, found in up to 2% of cases [3]. A loss-of-function variant in PCSK9 (R46L) is actually protective, lowering LDL cholesterol [2].

These markers are detected through genetic testing, often via DNA sequencing. The presence of a pathogenic mutation in one of these genes confirms a diagnosis of FH, which causes severely high LDL cholesterol from birth and a high lifetime risk of early heart disease [5]. However, a negative test does not rule out the condition, as mutations in other genes or a combination of multiple less-severe variants can also cause high cholesterol [1, 6].

My call: genetic markers for inherited high cholesterol are real and well-validated, but testing is most useful when a person has a strong family history or very high LDL levels. Confidence: high.

Keep digging

Sources used 6

  1. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease Journal of Clinical Lipidology (2018) Thin

    This study investigates the genetic variants associated with oligogenic familial hypercholesterolemia and their impact on LDL cholesterol levels and coronary artery disease risk among Japanese patients with elevated LDL cholesterol.

    DOI: 10.1016/j.jacl.2018.08.006
  2. Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief Report Arteriosclerosis, Thrombosis, and Vascular Biology (2017) Thin

    In the EPIC-Norfolk cohort, carriers of the PCSK9 R46L loss-of-function variant display an antiatherogenic lipoprotein profile measured by nuclear magnetic resonance (NMR), with lower atherogenic lipoprotein subfractions and lipids and a trend toward reduced CHD risk compared wi…

    DOI: 10.1161/ATVBAHA.116.307995
  3. Exploring Multi-Omics Approaches to Familial Hypercholesterolemia in the Middle East Advancements in Life Sciences (2025) Thin

    A comprehensive review of how multi-omics approaches are being applied to familial hypercholesterolemia in Middle Eastern populations, highlighting region-specific genetic variants, diagnostic challenges, and prospects for precision medicine.

    DOI: 10.62940/als.v12i4.3857
  4. Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in the Netherlands Clinical Genetics (2000) Thin

    An extensive mutational survey of the LDL receptor gene in Dutch familial hypercholesterolemia shows four common mutations accounting for about 22% of cases and expands the Dutch LDLR mutation spectrum to 61 mutations, including 16 novel substitutions and four small indels detec…

    DOI: 10.1034/j.1399-0004.2000.570205.x
  5. Differences in Phenotype, Genotype and Cardiovascular Events Between Patients with Probable and Definite Heterozygous Familial Hypercholesterolemia Personalized Medicine (2019) Thin

    In a Chinese cohort of 325 individuals diagnosed with probable or definite heterozygous familial hypercholesterolemia (HeFH) by DLCN criteria, definite HeFH showed a more severe phenotype and genotype, higher LDL-C and related biomarkers, more FH mutations, greater coronary arte…

    DOI: 10.2217/pme-2018-0135
  6. Analysis of a deeply-phenotyped familial hypercholesterolemia cohort from Mexico shows a role for both rare and common alleles across known dyslipidemia genes and reveals structural variation in a novel locus Human Genomics (2025) Thin

    A deeply phenotyped cohort of 300 Mexican familial hypercholesterolemia (FH) patients was analyzed with exome and genome sequencing, ancestry-aware polygenic risk profiling, and CNV analysis to show contributions from rare pathogenic mutations and common variants across known dy…

    DOI: 10.1186/s40246-025-00831-9

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question